MedTrace Logo

Weekly Docetaxel Plus Cisplatin as the First-line Therapy for Nasopharyngeal Cancer

NCT01312311 · Status: UNKNOWN · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 51

Last updated 2011-03-10

No results posted yet for this study

Summary

The investigators will evaluate weekly docetaxel plus 3-weekly cisplatin regimen as the first-line therapy for recurrent of metastatic nasophayngeal cancer

Conditions

  • Nasopharyngeal Cancer

Interventions

DRUG

Docetaxel, Cisplatin

Docetaxel 35mg/m2 D1 \& D8 Cisplatin 70mg/m2 D1

Sponsors & Collaborators

  • Samsung Medical Center

    lead OTHER

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2006-07-31
Primary Completion
2011-05-31

Countries

  • South Korea

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01312311 on ClinicalTrials.gov